Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Xenon Pharmaceuticals Inc. (XENE)

54.26 -0.98 (-1.77%)
At close: April 27 at 4:00:00 PM EDT
55.20 +0.94 (+1.73%)
After hours: April 27 at 6:13:36 PM EDT
Trade XENE on Coinbase
Chart Range Bar
Loading chart for XENE
Chart does not reflect overnight price.
  • Previous Close 55.24
  • Open 55.03
  • Bid 54.14 x 100
  • Ask 54.32 x 100
  • Day's Range 54.02 - 56.11
  • 52 Week Range 28.19 - 63.95
  • Volume 678,228
  • Avg. Volume 1,347,895
  • Market Cap (intraday) 5.244B
  • Beta (5Y Monthly) 0.75
  • PE Ratio (TTM) --
  • EPS (TTM) -4.36
  • Earnings Date (est.) May 11, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 79.24

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

www.xenon-pharma.com

358

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: XENE

Trailing total returns as of 4/27/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

XENE
21.06%
S&P 500 (^GSPC)
4.80%

1-Year Return

XENE
44.23%
S&P 500 (^GSPC)
29.84%

3-Year Return

XENE
37.79%
S&P 500 (^GSPC)
73.48%

5-Year Return

XENE
193.30%
S&P 500 (^GSPC)
71.35%

Earnings Trends: XENE

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -105.26M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-100M
-80M
-60M
-40M
-20M
0

Analyst Insights: XENE

View More

Analyst Price Targets

58.58
79.24 Average
54.26 Current
100.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/16/2026
Analyst Wedbush
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 64 -> 63

Statistics: XENE

View More

Valuation Measures

Annual
As of 4/24/2026
  • Market Cap

    5.33B

  • Enterprise Value

    4.79B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    583.31

  • Price/Book (mrq)

    9.17

  • Enterprise Value/Revenue

    639.17

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -32.58%

  • Return on Equity (ttm)

    -51.76%

  • Revenue (ttm)

    7.5M

  • Net Income Avi to Common (ttm)

    -345.91M

  • Diluted EPS (ttm)

    -4.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    548.89M

  • Total Debt/Equity (mrq)

    1.37%

  • Levered Free Cash Flow (ttm)

    -175.08M

Compare To: XENE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: XENE

Fair Value

54.26 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: